Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will
receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be
assessed for safety, tolerability, pharmacokinetics, and antiviral activity.